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1021-101 Association of Glomerular Filtration Rate on 
Presentation With Subsequent Mortality in Non- ST 
Elevation Acute Coronary Syndromes
Raphaelle Dumaine, C Michael Gibson, Duane S. Pinto, Sabina A. Murphy, David A. 
Morrow, Hans-Peter Hobbach, Stephen D. Wiviott, Christopher P. Cannon, Elliott M. 
Antman, Eugene Braunwald, TIMI Study Group, Boston, MA
Background: Renal function impairment is associated with poor prognosis in the setting
of ST-elevation myocardial infarction.
Methods: We hypothesized that decreased glomerular filtration rate (GFR) was associ-
ated with poor short- and long-term prognosis in patients with non ST-elevation acute
coronary syndromes (NSTE-ACS). Data were pooled from NSTE-ACS TIMI trials, and
patients were divided in 3 groups: with normal (>=90 mL/min/1.73m2,group 1, n=4952),
mildly decreased (60-89 mL/min/1.73m2, group 2, n=6262) and moderately to severely
decreased GFR (<60 mL/min/1.73m2, group 3, n=2093) on presentation.
Results: Mortality increased stepwise with decreasing GFR: 1.27%, 2.11%, and 5.02%
at 30 days and 2.47%, 3.79% and 9.53% at 6 months in groups 1, 2, and 3 respectively
(p<0.0001 for both). The combination of TIMI risk score (TRS) tertiles and decreasing
tertiles of GFR provided further mortality stratification with highest 6-month mortality rate
(15.44%) in lowest GFR combined with highest TRS (figure). Furthermore, decreased
GFR was associated with mortality independent of TRS (at 30 days, OR=1.41 in group 2,
p=0.03; OR=3.11 in group 3, p<0.001). In addition, stroke incidence at 30-day increased
with decreased GFR: 0.33%, 0.59% and 1.27 % in groups 1, 2, and 3 respectively
(p<0.0001).
Conclusion: In the setting of NSTE-ACS, impaired GFR is associated with increased 30-
day and 6-month mortality independent of TRS, and is associated with increased stroke
incidence at 30 days.
1021-102 Underachievement of Low-Density Lipoprotein 
Cholesterol Goal in Patients on Statins in Clinical 
Practice: Are We Using Low Doses of Statins Too 
Often?
Alexandria J.M. Braganza, Gemma Eminowicz, Sabina A. Murphy, Peter M. DiBattiste, 
Gregory C. Flaker, Christopher P. Cannon, Brigham and Women's Hospital, Boston, MA
Background:Although clinical trials have found significant reductions in cardiovascular
events when using fixed doses of statins (e.g. 40 mg of simvastatin or pravastatin), in
clinical practice, treatment is usually initiated at lower doses. It is not clear, however, if in
clinical practice, the doses are titrated upward after the initial dose.
Methods: Among 2220 patients with non-ST elevation acute coronary syndromes, we
examined the statin doses used in those receiving statins at the time of entry in the TAC-
TICS-TIMI 18 trial, and their relationship to the measured low-density lipoprotein choles-
terol (LDL-C) on admission.
Results: At study entry, 722 (33%) patients were on statins, of whom 372 had LDL-C
measurements available: 132 (35%) were on atorvastatin, 126 (34%) on simvastatin, 58
(16%) on pravastatin, and 15% on other statins. The doses used are shown in the Figure.
Only 17% and 36% of patients were treated with the 40 mg doses of pravastatin or simv-
astatin as used in clinical trials. Only 1% of patients were treated with 80mg atorvastatin.
At entry, only 47% of these patients had LDL-C <100 mg/dl. At 6 months, although more
patients (1129, 51%) were on statins, the doses of statins used were not higher than
those used at baseline.
Conclusion: With the large number of patients on low doses of statins, and the majority
not being at LDL-C goal, our data suggest that, in addition to previously documented
underutilization of statins in clinical practice, there is also under-dosing of this important
class of drugs.
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1022-79 Is Early Prehospital Administration of Abciximab 
Superior to Periprocedural Therapy in Patients With ST-
Segment Elevation Myocardial Infarction and Planned 
Percutaneous Coronary Intervention? Early and Late 
Results From the Randomized REOMOBILE Pilot Study
Hans-Richard Arntz, Joachim Schröder, Klaus Pels, Bernhard Witzenbichler, Peter 
Schwimmbeck, Dirk Müller, Heinz-Peter Schultheiss, Benjamin Franklin Medical Center, 
Berlin, Germany
Background: Pre-treatment of pts with STEMI with abciximab already in the mobile inten-
sive care unit (MICU) is believed to facilitate percutaneous coronary intervention (PCI)
and improve outcome.
Methods: We randomised 100 pts with STEMI (age <80 yrs, symptoms <6hrs) to receive
weight adjusted abciximab at the scene (PTx, n=52) or at intervention in the cath lab
(HTx, n=48). All pts received 500 mg aspirin and 70 U/kg heparin in the MICU.
Results: Groups were balanced for sex (19% female), age (median 63 yrs), localisation of
MI (39% anterior) and symptom duration to arrival of MICU (median 50 min). Median
duration of symptoms until abciximab injection was 68 min in pts with PTx and 164 min
with HTx. Symptom duration to 1st visualisation of infarct related artery was 142 min in
pts with PTx and 152 min with HTx respectively. ST segment resolution after 60-90 min
(before PCI with PTx) was < 30% in 39%, 30-70% in 37% and >70% in 24% of pts, com-
pared to 56%, 14%, and 30% with HTx respectively. With PTx initial TIMI-flow 0/1 was
present in 48%, and TIMI-flow 2/3 in 52%, compared to 52% and 48% with HTx respec-
tively. Blush grade before intervention with PTx was 0/1 in 63%, and 2/3 in 37%, com-
pared to 66% and 34% with HTx respectively. Stents were successfully placed in 93% of
pts. TIMI-flow 3 was achieved in 88% of pts with PTx and 82% with HTx. None of the dif-
ferences were significant. Results tended to be in favour of PTx in pts who were treated
within the 1st hour after symptom onset independent of the time interval between start of
treatment and 1st visualisation of IRA. One HTx-pt died on day 4 after prolonged resusci-
tation, two pts had major bleeds (1 PTx, 1HTx). Urgent CABG was performed in 7 pts (4
PTx, 3 HTx) until day 5. Until day 180, three pts with PTx had reinfarctions, two within 30
days, one during month 4. Ten pts had ischemia driven re-PCI of IRA (5 PTx, 5 HTx),
three of these within the first 30 days after the index event.
Conclusion: Pre-hospital application of abciximab is safe and feasible. However, in some
contrast to previous reports we found only minor advantages of abciximab pre-treatment
in pts with STEMI and planned PCI. Also fast-track pre-hospital procedures in general
may have added essentially to the excellent outcome of the pts.
Fasting glucose 
(mg/dl)
HDL 
(mg/dl)
TRIG 
(mg/dl)
BMI (kg/
m2)
Total Chol. 
(mg/dl)
Mean Value
MS+
126 38 216 32 200
Median Values 
MS +
117 37 182 32 194
Mean Value
MS -
110 44 119 26 182
Median Value
MS-
102 42 117 26 174
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1022-80 Safety and Feasibility of Paclitaxel-Eluting Stents in the 
Treatment of ST-Elevation Acute Myocardial Infarction
Andrew T. L Ong, Pedro A. Lemos, Angela Hoye, Chourmouzios A. Arampatzis, 
Francesco Saia, Jiro Aoki, Carlos van Mieghem, Sjoerd H. Hofma, Pieter C. Smits, 
Willem J. van der Giessen, Georgios Sianos, Eugene McFadden, Pim de Feyter, Patrick 
W. Serruys, Thoraxcenter, Rotterdam, The Netherlands
Background: Paclitaxel-eluting stents (PES) have been shown to markedly reduce rest-
enosis in elective patients. To date, there have been no studies evaluating their role in the
treatment of ST-Elevation Myocardial Infarction.
Method: Paclitaxel-eluting stents have been utilised as the default strategy for all patients
at our institution as part of the Taxus-Stent Evaluated At Rotterdam Cardiology Hospital
(T-SEARCH) Registry. Patients who received other types of drug eluting stents were not
eligible for the registry. From 10 March 2003 to 11 July 2003, ninety seven consecutive
patients were treated for ST elevation acute myocardial infarction with at least one PES.
One patient was excluded from the analysis as his acute myocardial infarction was sec-
ondary to subacute thrombosis.
Results: Seventy-eight patients underwent primary PCI while the remainder were treated
following failed thrombolytic therapy. Multi vessel disease was present in 39% of patients,
with an average of 1.26 vessels treated per patient. The RCA and LAD accounted for
44% and 39% of vessels treated respectively. Forty one percent of patients received gly-
coprotein IIb/IIIa inhibitors.
Subacute thrombosis was seen in one patient an hour after the index procedure while a
second patient required thrombolytic therapy for new ST elevation four days after the
index procedure. A further two patients developed symptoms four and six days following
bifurcation stenting. These patients had angiographic evidence of subacute thrombosis.
Six-month follow-up data will be available for these patients at the time of presentation.
Conclusion: This is the first study to evaluate the safety and feasibility of PES in the set-
ting of acute myocardial infarction. Bifurcation stenting in acute myocardial infarction
appears to predispose to the development of subacute stent thrombosis.
1022-81 Short Door-to-Balloon Times With Primary 
Percutaneous Coronary Intervention for Acute 
Myocardial Infarction Improve Late Survival in Patients 
With Early, but Not Late Presentation
Bruce R. Brodie, Thomas D. Stuckey, Charles J. Hansen, Debra S. VerSteeg, Denise B. 
Muncy, Navin Gupta, William Downey, LeBauer Cardiovascular Research Foundation 
and Moses Cone Heart and Vascular Center, Greensboro, NC, NC
Background: The importance of door-to-balloon time (DBT) with primary PCI for AMI is
controversial.
Methods: Consecutive pts (n=2,117) with ST-segment elevation AMI treated with pri-
mary PCI were prospectively enrolled in a registry and followed clinically for 6.5 years
(mean).
Results: DBT (<1.5 vs >1.5-2 vs >2-3 vs >3 hrs) was highly correlated with in-hospital
mortality (5.2% vs 7.0% vs 11.4% vs 14.2%, p<0.0001) and late cardiac mortality (23.3%
vs 25.8% vs 30.0% vs 34.7%, p<0.0001). After adjusting for differences in baseline vari-
ables, DBT >2 hrs was a strong independent predictor of late mortality (OR 1.31 95% CI
1.07-1.61, p=0.008). However, prolonged DBT (>2 hrs) was associated with increased
mortality only in patients presenting early (<2 hrs) (n=891) (OR 1.32 95% CI 1.08-1.62,
p=0.007), and had little effect on mortality in patients presenting late (>2 hrs) (n=1206)
(OR 1.17 95% CI 0.82-1.67, p=0.39)
Conclusion: Rapid time to treatment with primary PCI improves late survival in patients
presenting early but is less critical in patients presenting late. These data are consistent
with previous observations that there is a window of opportunity during which early reper-
fusion with primary PCI can result in superior outcomes, after which further delays in
treatment have much less effect on mortality. These observations have implications
regarding the triage of patients for primary PCI. 
1022-82 A Prospective, Randomized Trial of Mild Hypothermia 
During Primary Percutaneous Intervention for Acute 
Myocardial Infarction (COOL-MI): One-Year Clinical 
Outcome
Simon R. Dixon, David G. Rizik, John J. Griffin, Joseph P. Carrozza, Barry D. Rutherford, 
Adnan Kastrati, Suku T. Thambar, Richard E. Kuntz, Raymond J. Gibbons, Jeffrey J. 
Popma, William W. O'Neill, The COOL-MI Investigators, William Beaumont Hospital, 
Royal Oak, MI, Sentara Virginia Beach General Hospital, Sentara, VA
Background: Mild hypothermia reduces infarct size in experimental models of acute
myocardial infarction (AMI). We conducted a prospective, randomized trial to evaluate the
safety and efficacy of mild hypothermia as an adjunct to primary percutaneous coronary
intervention (PCI) for AMI.
Methods: Three hundred-fifty seven patients with acute ST-segment elevation MI (<6-
hours from symptom-onset) were assigned to undergo primary PCI with or without
adjunctive cooling. Hypothermia was induced using the ReprieveTM Endovascular Tem-
perature Therapy System (Radiant Medical Inc., Redwood City, CA). Patients were
cooled to a target core temperature of 33oC for 3 hours after reperfusion. The primary
effectiveness endpoint of the trial was final infarct size at 30-days measured using 99mTc-
sestamibi SPECT imaging. The primary safety endpoint was major adverse cardiac
events (MACE) at 30-days. Clinical follow-up was performed at 6 and 12-months.
Results: One hundred seventy-seven patients were randomized to PCI with adjunctive
hypothermia. The mean duration of cooling before reperfusion was 18 minutes (mean
core temperature at first balloon inflation = 35oC). 72% patients reached the target core
temperature (mean time to target = 75 minutes). Cooling was well tolerated. There were
no significant adverse clinical events related to endovascular cooling. Final infarct size in
the hypothermia group was not significantly different from the control group (14.1% vs.
13.8%, p=0.83). MACE at 30-days was similar in both groups (cooling 6.2% vs. control
3.9%, p=0.45). Patients with anterior infarction who had a core temperature of <35oC at
reperfusion had a significantly smaller infarct size compared to both those patients with a
temperature >35oC at reperfusion (9.3% vs. 21.9%, p=0.01), and controls (9.3% vs.
18.2%, p=0.05). Late clinical follow-up is in currently progress.
Conclusion: Endovascular cooling is safe and well tolerated during mechanical reperfu-
sion for AMI. One-year clinical outcome data will be presented for the overall patient pop-
ulation, and the anterior infarct subgroup with a temperature <35oC at reperfusion in
which a reduction in infarct size was observed.
1022-83 The Impact of Insulin-Requiring Diabetes Mellitus on 
Effectiveness of Reperfusion and Outcome of Patients 
Undergoing Primary Percutaneous Coronary 
Intervention for Acute Myocardial Infarction
David Antoniucci, Renato Valenti, Angela Migliorini, Guido Parodi, Guia Moschi, Gentian 
Memisha, Giovanni M. Santoro, Giampaolo Cerisano, Careggi Hospital, Florence, Italy
Background Diabetes mellitus (DM) independently predicts mortality after thrombolytic
therapy for acute myocardial infarction (AMI), while previous studies on outcome of dia-
betics undergoing primary percutaneous coronary intervention (PCI) for AMI did not con-
firm the relationship between DM and mortality.
Methods The relationship between DM and six-month clinical outcome was assessed in
a series of 1,071 patients with AMI who underwent primary PCI. DM was considered
present if the diagnosis had been done before admission. Patients with DM were catego-
rized based on insulin/noninsulin treatment. The efficacy of reperfusion was assessed by
ST-segment resolution analysis at 30 min after infarct artery recanalization.
Results Out of 1,071 patients, 903 (84%) were non-DM and 168 had DM (16%). Among
DM patients, 86 (51%) patients had insulin-requiring DM. Insulin-requiring DM patients
had a worse risk profile as compared to the one of the other groups. Insulin-requiring DM
patients were older, more frequently women, had a greater incidence of cardiogenic
shock, 3-vessel disease and chronic occlusion. Primary PCI success was 97% in non-
DM patients, 98% in insulin-requiring DM patients and 94% in non-insulin-requring DM
patients. Early ST-segment resolution rate was lower in insulin-requiring DM patients
(52%) as compared to the other DM patients (78%), and non-DM patients (76%; p <
0.001). The 6-month mortality rate was 26% in insulin-requiring DM patients, 7% in non-
DM patients, and 4% in non-insulin-requiring DM patients (p < 0.001). Multivariate analy-
sis showed insulin-requiring DM to be independently related to the risk of death (HR
1.94, 95% CI 1.17-3.21, p = 0.010).Conclusions Insulin-requiring DM is a strong predic-
tor of mortality in patients undergoing PCI for AMI, and this relationship may be explained
by a less effective myocardial reperfusion despite mechanical restoration of a normal epi-
cardial flow in most patients.
1022-84 Survival Benefits of Primary Angioplasty Over 
Thrombolysis After Adjustment for Percutaneous 
Transluminal Coronary Angioplasty Related Time Delay
Giuseppe Tarantini, Angelo Ramondo, Massimo Napodano, Paolo Buja, Giambattista 
Isabella, Claudio Bilato, Renato Razzolini, Sabino Iliceto, University of Padua, Padua, 
Italy
Time to treatment remains a critical determinant of outcome after acute myocardial inf-
arction regardless of the strategy of reperfusion used. We investigated the relationship
between primary angioplasty (PTCA)-related delay and the benefits of PTCA, by review-
ing the results of randomized trials comparing PTCA with thrombolytic therapy (Rx). The
SHOCK trial was not considered in our analysis, Akhras’s trial was excluded because the
full data set was not available. DANAMI 2 study was considered as two separated sub-
studies (invasive and referral centers). We calculated the following:
PTCA - related delay = median “door to balloon” time – median “door to needle” time
Survival benefit= 30 day mortality after Rx – 30 day mortality after PTCA. Relationship
between delay and benefit was assessed by linear regression. Reported PTCA - related
